{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:50:40Z","timestamp":1791899440354,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jsat.2021.108405","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T21:40:52Z","timestamp":1618954852000},"page":"108405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study"],"prefix":"10.1016","volume":"130","author":[{"given":"Matthew","family":"Robbins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Haroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Mazzarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"IV","given":"David","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Salzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2021.108405_bb0005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jsat.2016.08.002","article-title":"Non-prescribed buprenorphine in New York City: Motivations for use, practices of diversion, and experiences of stigma","volume":"70","author":"Allen","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"8","key":"10.1016\/j.jsat.2021.108405_bb0010","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3109\/10826084.2014.888449","article-title":"Self-management of buprenorphine\/naloxone among online discussion board users","volume":"49","author":"Brown","year":"2014","journal-title":"Substance Use & Misuse"},{"issue":"6","key":"10.1016\/j.jsat.2021.108405_bb0015","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/ADM.0000000000000436","article-title":"The more things change: Buprenorphine\/naloxone diversion continues while treatment remains inaccessible","volume":"12","author":"Carroll","year":"2018","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2021.108405_bb0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugalcdep.2018.09.007","article-title":"Understanding the use of diverted buprenorphine","volume":"193","author":"Cicero","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108405_bb0025","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.drugalcdep.2014.06.005","article-title":"Factors contributing to the rise of buprenorphine misuse: 2008-2013","volume":"142","author":"Cicero","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108405_bb0030","doi-asserted-by":"crossref","first-page":"107574","DOI":"10.1016\/j.drugalcdep.2019.107574","article-title":"Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis","volume":"204","author":"Daniulaityte","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"7","key":"10.1016\/j.jsat.2021.108405_bb0035","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1176\/ajp.2006.163.7.1233","article-title":"The availability of web sites offering to sell opioid medications without prescriptions","volume":"163","author":"Forman","year":"2006","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.jsat.2021.108405_bb0040","doi-asserted-by":"crossref","unstructured":"Ghertner R. U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018. (2019). Drug Alcohol Depend, 1;204:107527.","DOI":"10.1016\/j.drugalcdep.2019.06.029"},{"key":"10.1016\/j.jsat.2021.108405_bb0045","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugalcdep.2016.03.028","article-title":"Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City","volume":"164","author":"Hansen","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.jsat.2021.108405_bb0050","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap) \u2013 A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"Journal of Biomedical Informatics"},{"key":"10.1016\/j.jsat.2021.108405_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2017.04.005","article-title":"Why aren\u2019t physicians prescribing more buprenorphine?","volume":"78","author":"Huhn","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1\u20133","key":"10.1016\/j.jsat.2021.108405_bb0060","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drugalcdep.2011.07.019","article-title":"Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians","volume":"120","author":"Johanson","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108405_bb0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jsat.2018.07.008","article-title":"Comparison between buprenorphine provider availability and opioid deaths among US counties","volume":"93","author":"Jones","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"9","key":"10.1016\/j.jsat.2021.108405_bb0070","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\/ethnicity and payment","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.jsat.2021.108405_bb0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1016\/j.jsat.2021.108405_bb0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsat.2014.02.003","article-title":"Abuse and diversion of buprenorphine sublingual tablets and film","volume":"47","author":"Lavonas","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.jsat.2021.108405_bb0085","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","article-title":"Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial","volume":"93","author":"Ling","year":"1998","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2021.108405_bb0090","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.drugpo.2019.06.019","article-title":"\u201cThey\u2019re making it so hard for people to get help\u201d: Motivations for non-prescribed buprenorphine use in a time of treatment expansion","volume":"71","author":"McLean","year":"2019","journal-title":"International Journal of Drug Policy"},{"issue":"3","key":"10.1016\/j.jsat.2021.108405_bb0095","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1080\/02791072.2019.1566583","article-title":"Barriers to buprenorphine expansion in Ohio: A time-elapsed qualitative study","volume":"51","author":"Molfenter","year":"2019","journal-title":"Journal of Psychoactive Drugs"},{"issue":"5","key":"10.1016\/j.jsat.2021.108405_bb0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.5734","article-title":"Assessment of racial and ethnic disparities in the use of medication to treat opioid use disorder among pregnant women in Massachusetts","volume":"3","author":"Schiff","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jsat.2021.108405_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2020.107958","article-title":"On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine","volume":"210","author":"Silverstein","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.jsat.2021.108405_bb0110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/08897077.2018.1449166","article-title":"A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees","volume":"39","author":"Stein","year":"2018","journal-title":"Substance Abuse"},{"issue":"5","key":"10.1016\/j.jsat.2021.108405_bb0115","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: Ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clinical Pharmacology and Therapeutics"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221001318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221001318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:54:27Z","timestamp":1760039667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221001318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":23,"alternative-id":["S0740547221001318"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108405","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108405"}}